Apricus Biosciences announced that the company has filed its response to questions received from Swissmedic, the Agency for Therapeutic Products in Switzerland, relating to its marketing application ...

SAN DIEGO, April 28, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it has filed a marketing application in Europe for Vitaros ® as a treatment ...

SAN DIEGO, May 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file a marketing application in Switzerland for Vitaros ® as a ...

Apricus Biosciences Inc (NASDAQ: APRI) receded 67.4 percent Friday and continued down Tuesday after the U.S. Food and Drug Administration issued a response letter for Vitaros. The FDA declined to ...

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its ...

EAST WINDSOR, N.J.--(BUSINESS WIRE)--October 20, 2008--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative treatments based on the NexACT ® technology, announced today that it met with the Food and ...

Apricus Biosciences, Inc. ( APRI) recently announced that its erectile dysfunction (ED) drug, Vitaros, has been approved under the European Decentralized Procedure (DCP). Apricus, along with its ...

Shares of Apricus Biosciences, Inc.APRI surged almost 90% after the company announced that its topical cream Vitaros was approved in Mexico for the treatment of patients with erectile dysfunction.

Apricus Biosciences, Inc. (NASDAQ: APRI) announced that it intends to resubmit its new drug application (NDA) for its drug Vitaros in 2017. Apricus had a Type B meeting with the FDA as previously ...

(www.apricusbio.com), today provided a corporate update. "Since the beginning of this year, we have continued to focus our efforts on creating long-term value through our lead product Vitaros® and our ...

The Company has one approved product, Vitaros (R), for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus Bio's marketing partners ...